Over the past decade, the therapeutic landscape for sickle cell disease and transfusion-dependent β-thalassaemia has evolved at an unprecedented rate. Allogeneic and autologous (gene edited) haematopoietic cell transplantation offer the possibility of a potential cure for selected individuals.
Despite national commissioning frameworks and increasing clinical experience, access to these potentially transformative treatments remains variable across the UK.

Read the full document

Comments are disabled.